Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has earned an average recommendation of “Moderate Buy” from the eighteen research firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $53.81.

TNDM has been the subject of a number of recent analyst reports. Royal Bank of Canada assumed coverage on Tandem Diabetes Care in a research report on Wednesday, October 2nd. They set an “outperform” rating and a $65.00 target price for the company. Canaccord Genuity Group decreased their target price on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Barclays upped their price target on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. The Goldman Sachs Group started coverage on shares of Tandem Diabetes Care in a research note on Friday, October 4th. They issued a “neutral” rating and a $46.00 price objective on the stock. Finally, Sanford C. Bernstein initiated coverage on Tandem Diabetes Care in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 price target on the stock.

Tandem Diabetes Care Trading Up 2.8 %

TNDM stock opened at $36.50 on Friday. Tandem Diabetes Care has a 52 week low of $21.85 and a 52 week high of $53.69. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The company’s 50-day simple moving average is $34.15 and its 200 day simple moving average is $37.75. The company has a market capitalization of $2.40 billion, a PE ratio of -18.91 and a beta of 1.29.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.08. The company had revenue of $243.97 million for the quarter, compared to analysts’ expectations of $224.14 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The business’s revenue for the quarter was up 31.4% on a year-over-year basis. During the same period last year, the firm earned ($0.38) earnings per share. As a group, sell-side analysts anticipate that Tandem Diabetes Care will post -1.68 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Kim D. Blickenstaff sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the sale, the director now directly owns 195,190 shares of the company’s stock, valued at approximately $5,855,700. This represents a 4.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 2.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tandem Diabetes Care

Several hedge funds and other institutional investors have recently bought and sold shares of TNDM. Brooklyn Investment Group bought a new position in Tandem Diabetes Care during the third quarter worth $28,000. Assetmark Inc. acquired a new position in shares of Tandem Diabetes Care during the third quarter valued at about $29,000. ORG Wealth Partners LLC acquired a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at about $30,000. Waldron Private Wealth LLC bought a new stake in Tandem Diabetes Care in the 3rd quarter valued at about $50,000. Finally, McIlrath & Eck LLC acquired a new position in Tandem Diabetes Care during the 3rd quarter worth approximately $52,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.